- Home
- CGON vs DAVA Comparison
CGON vs DAVA Comparison
Compare CGON & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- DAVA
- Stock Information
- Founded
- CGON 2010
- DAVA 2000
- Country
- CGON United States
- DAVA United Kingdom
- Employees
- CGON N/A
- DAVA N/A
- Industry
- CGON
- DAVA EDP Services
- Sector
- CGON
- DAVA Technology
- Exchange
- CGON NYSE
- DAVA Nasdaq
- Market Cap
- CGON 1.3B
- DAVA 1.2B
- IPO Year
- CGON 2024
- DAVA 2018
- Fundamental
- Price
- CGON $23.74
- DAVA $19.88
- Analyst Decision
- CGON Strong Buy
- DAVA Buy
- Analyst Count
- CGON 11
- DAVA 12
- Target Price
- CGON $62.90
- DAVA $39.43
- AVG Volume (30 Days)
- CGON 2.0M
- DAVA 481.5K
- Earning Date
- CGON 05-20-2025
- DAVA 05-14-2025
- Dividend Yield
- CGON N/A
- DAVA N/A
- EPS Growth
- CGON N/A
- DAVA N/A
- EPS
- CGON N/A
- DAVA 0.12
- Revenue
- CGON $1,139,000.00
- DAVA $950,741,765.00
- Revenue This Year
- CGON N/A
- DAVA $9.52
- Revenue Next Year
- CGON $16,237.24
- DAVA $7.60
- P/E Ratio
- CGON N/A
- DAVA $170.81
- Revenue Growth
- CGON 461.08
- DAVA N/A
- 52 Week Low
- CGON $14.80
- DAVA $16.60
- 52 Week High
- CGON $40.47
- DAVA $34.94
- Technical
- Relative Strength Index (RSI)
- CGON 49.91
- DAVA 56.60
- Support Level
- CGON $21.00
- DAVA $18.50
- Resistance Level
- CGON $30.23
- DAVA $20.80
- Average True Range (ATR)
- CGON 2.33
- DAVA 0.78
- MACD
- CGON 0.06
- DAVA 0.39
- Stochastic Oscillator
- CGON 30.94
- DAVA 75.98
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the U.K. and it continues to generate the majority of revenue in the U.K. and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.